WO1997002344A3 - Vaccin contre des agents infectieux, composition pour le traitement et la prevention des infections a hiv - Google Patents

Vaccin contre des agents infectieux, composition pour le traitement et la prevention des infections a hiv Download PDF

Info

Publication number
WO1997002344A3
WO1997002344A3 PCT/FR1996/001006 FR9601006W WO9702344A3 WO 1997002344 A3 WO1997002344 A3 WO 1997002344A3 FR 9601006 W FR9601006 W FR 9601006W WO 9702344 A3 WO9702344 A3 WO 9702344A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
vaccine
composition
hiv infections
preventing hiv
Prior art date
Application number
PCT/FR1996/001006
Other languages
English (en)
Other versions
WO1997002344A2 (fr
Inventor
Jean-Claude Chermann
Contel Carole Le
Pascale Galea
Original Assignee
Inst Nat Sante Rech Med
Chermann Jean Claude
Contel Carole Le
Pascale Galea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US08/973,551 priority Critical patent/US6113902A/en
Priority to AU64623/96A priority patent/AU6462396A/en
Priority to DE69615685T priority patent/DE69615685T2/de
Priority to EP96924033A priority patent/EP0835309B1/fr
Priority to DK96924033T priority patent/DK0835309T3/da
Priority to JP50486697A priority patent/JP4036895B2/ja
Application filed by Inst Nat Sante Rech Med, Chermann Jean Claude, Contel Carole Le, Pascale Galea filed Critical Inst Nat Sante Rech Med
Priority to AT96924033T priority patent/ATE206456T1/de
Publication of WO1997002344A2 publication Critical patent/WO1997002344A2/fr
Publication of WO1997002344A3 publication Critical patent/WO1997002344A3/fr
Priority to US11/220,407 priority patent/US20060073165A1/en
Priority to US12/479,399 priority patent/US20100167265A1/en
Priority to US12/970,883 priority patent/US20110262894A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un vaccin destiné au traitement et/ou à la prévention de maladies d'origine infectieuse, l'agent infectieux ayant au moins une phase intracellulaire chez l'hôte lors de son cycle de multiplication, caractérisé en ce qu'il comporte au moins un épitope cryptique d'un élément cellulaire emporté par un agent infectieux intracellulaire lors de son passage à l'extérieur de la cellule et qui est dévoilé par l'agent infectieux. Elle concerne également une composition destinée au traitement ou à la prévention des infections à HIV, des anticorps dirigés contre un peptide d'intérêt et un procédé de diagnostic.
PCT/FR1996/001006 1995-06-30 1996-06-28 Vaccin contre des agents infectieux, composition pour le traitement et la prevention des infections a hiv WO1997002344A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU64623/96A AU6462396A (en) 1995-06-30 1996-06-28 Vaccine for infectious agents, composition for treating and preventing hiv infections
DE69615685T DE69615685T2 (de) 1995-06-30 1996-06-28 Impstoff gegen krankheitserreger, zusammensetzung zur behandlung und vorbeugung von hiv infektionen
EP96924033A EP0835309B1 (fr) 1995-06-30 1996-06-28 Vaccin contre des agents infectieux, composition pour le traitement et la prevention des infections a hiv
DK96924033T DK0835309T3 (da) 1995-06-30 1996-06-28 Vaccine imod infektiøse agenser, præparat til behandling og forebyggelse af HIV infektioner
JP50486697A JP4036895B2 (ja) 1995-06-30 1996-06-28 細胞内相を有する感染性病原体に対するワクチン、ｈｉｖ感染の治療および予防用組成物、抗体と診断方法
US08/973,551 US6113902A (en) 1995-06-30 1996-06-28 Immunogenic compositions comprising peptides from β-2-microglobulin
AT96924033T ATE206456T1 (de) 1995-06-30 1996-06-28 Impstoff gegen krankheitserreger, zusammensetzung zur behandlung und vorbeugung von hiv infektionen
US11/220,407 US20060073165A1 (en) 1995-06-30 2005-09-07 Vaccine against infectious agents having an intracellular phase, composition for the treatment and prevention of HIV infections, antibodies and method of diagnosis
US12/479,399 US20100167265A1 (en) 1995-06-30 2009-06-05 Vaccine against infectious agents having an intracellular phase, composition for the treatment and prevention of hiv infections, antibodies and method of diagnosis
US12/970,883 US20110262894A1 (en) 1995-06-30 2010-12-16 Vaccine against infectious agents having an intracellular phase, composition for the treatment and prevention of hiv infections, antibodies and methods of diagnosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR95/07914 1995-06-30
FR9507914A FR2735984B1 (fr) 1995-06-30 1995-06-30 Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US59954900A Continuation 1995-06-30 2000-06-23

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US08973551 A-371-Of-International 1998-02-19
US59954900A Division 1995-06-30 2000-06-23
US09/827,345 Division US20030021800A1 (en) 1995-06-30 2001-04-06 Vaccine against infectious agents having an intracellular phase, composition for the treatment and prevention of HIV infections, antibodies and method of diagnosis

Publications (2)

Publication Number Publication Date
WO1997002344A2 WO1997002344A2 (fr) 1997-01-23
WO1997002344A3 true WO1997002344A3 (fr) 1997-03-06

Family

ID=9480577

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1996/001006 WO1997002344A2 (fr) 1995-06-30 1996-06-28 Vaccin contre des agents infectieux, composition pour le traitement et la prevention des infections a hiv

Country Status (13)

Country Link
US (1) US6113902A (fr)
EP (1) EP0835309B1 (fr)
JP (1) JP4036895B2 (fr)
CN (1) CN1117148C (fr)
AT (1) ATE206456T1 (fr)
AU (1) AU6462396A (fr)
CA (1) CA2223825A1 (fr)
DE (1) DE69615685T2 (fr)
DK (1) DK0835309T3 (fr)
ES (1) ES2165510T3 (fr)
FR (1) FR2735984B1 (fr)
PT (1) PT835309E (fr)
WO (1) WO1997002344A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2235420A1 (fr) 1998-06-17 1999-12-17 Paolo Renzi Oligonucleoside antisens pour traiter ou prevenir les maladies atopiques et la proliferation de cellules neoplastiques
FR2836146B1 (fr) * 2002-02-15 2005-01-07 Urrma R & D IMMUNOGLOBULINE IgG3 MARQUEUR DE PROTECTION CONTRE LES MALADIES VIRALES INFECTIEUSES ET SES UTILISATIONS
CN1745094A (zh) * 2002-12-06 2006-03-08 新加坡综合医院有限公司 肽,其抗体,以及它们在中枢神经系统损伤的治疗中的用途
TW200846363A (en) * 2007-03-22 2008-12-01 Urrma R & B Novel human anti-R7V antibodies and uses thereof
EP2374470A1 (fr) * 2010-04-08 2011-10-12 Beta Innov Utilisation thérapeutique de la protéine Beta2m
EP3512551A4 (fr) * 2016-09-16 2020-08-05 The Brigham and Women's Hospital, Inc. Blocus d'interactions de l'alphaf toprotéine (afp) avec des molécules associées à la microglobuline bêta2

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018630A1 (fr) * 1991-04-18 1992-10-29 Fondation Nationale De Transfusion Sanguine Compose comprenant une sequence peptidique neutralisant l'infection par le cytomegalovirus humain (hcmv) et composition le comportant
WO1993014126A1 (fr) * 1992-01-17 1993-07-22 Medical Research Council Antigene de classe ii du complexe d'histocompatibilite majeure utilise dans un vaccin contre un virus d'immunodeficience
WO1994001130A1 (fr) * 1992-07-13 1994-01-20 Medical Research Council Antigene du complexe majeur d'histocompatibilite utilise comme vaccin contre un virus d'immuno-deficience
WO1994024290A1 (fr) * 1993-04-08 1994-10-27 British Bio-Technology Limited Proteines resultant de la fusion entre des sequences d'acides amines antigeniques et la beta-2-microglobuline

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK160944C (da) * 1986-01-16 1991-10-21 Novo Industri As Modificerede beta2-mikroglobuliner og farmaceutiske praeparater indeholdende disse
US5733550A (en) * 1990-05-10 1998-03-31 Dana-Farber Cancer Institute, Inc. Method for enhancing the association of exogenous peptides with class I MHC molecules on the surface of antigen presenting cells with β-microglobulin
US6696061B1 (en) * 1992-08-11 2004-02-24 President And Fellows Of Harvard College Immunomodulatory peptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018630A1 (fr) * 1991-04-18 1992-10-29 Fondation Nationale De Transfusion Sanguine Compose comprenant une sequence peptidique neutralisant l'infection par le cytomegalovirus humain (hcmv) et composition le comportant
WO1993014126A1 (fr) * 1992-01-17 1993-07-22 Medical Research Council Antigene de classe ii du complexe d'histocompatibilite majeure utilise dans un vaccin contre un virus d'immunodeficience
WO1994001130A1 (fr) * 1992-07-13 1994-01-20 Medical Research Council Antigene du complexe majeur d'histocompatibilite utilise comme vaccin contre un virus d'immuno-deficience
WO1994024290A1 (fr) * 1993-04-08 1994-10-27 British Bio-Technology Limited Proteines resultant de la fusion entre des sequences d'acides amines antigeniques et la beta-2-microglobuline

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LE CONTEL C ET AL: "Identification of the beta-2m derived epitope responsible for neutralization of HIV isolates.", CELLULAR PHARMACOLOGY 3 (2). 1996. 68-73, XP000616506 *

Also Published As

Publication number Publication date
DE69615685D1 (de) 2001-11-08
WO1997002344A2 (fr) 1997-01-23
DK0835309T3 (da) 2002-12-02
ATE206456T1 (de) 2001-10-15
CN1193349A (zh) 1998-09-16
CN1117148C (zh) 2003-08-06
PT835309E (pt) 2002-03-28
AU6462396A (en) 1997-02-05
JP4036895B2 (ja) 2008-01-23
DE69615685T2 (de) 2002-08-08
US6113902A (en) 2000-09-05
FR2735984A1 (fr) 1997-01-03
CA2223825A1 (fr) 1997-01-23
JPH11509407A (ja) 1999-08-24
EP0835309A2 (fr) 1998-04-15
FR2735984B1 (fr) 1997-09-19
EP0835309B1 (fr) 2001-10-04
ES2165510T3 (es) 2002-03-16

Similar Documents

Publication Publication Date Title
CA2144043A1 (fr) Anticorps monoclonaux humains neutralisants diriges contre le virus respiratoire syncytial
EP0777497A4 (fr) Anticorps monoclonaux humains neutralisant le virus de l'immunideficience humaine
NL930133I2 (nl) Vaccin tegen hepatitis B virus, werkwijze en getransformeerde eukaryotische cellen en de bereiding van dat vaccin.
WO1997019111A3 (fr) Anticorps monoclonaux anti-cd6 et leurs utilisations
CA2381770A1 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
AU5055593A (en) Antibodies specific for HIV
AR001686A1 (es) Una composición vacuna un proceso para prepararla y su uso para la fabricación de una vacuna
WO1997008318A3 (fr) Composes et procedes de traitement et de diagnostic du cancer de la prostate
AU6832398A (en) Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
DE69720056D1 (de) Chlamydia-impfstoffe und immunogene chlamydia-zusammensetzungen, die ein antigen der äusseren membran enthalten, sowie verfahren zu deren herstellung
NL168220B (nl) Werkwijze voor het binden van biologisch actieve pro- teinen, alsmede werkwijze voor het bereiden van een verbinding, geschikt voor gebruik bij voornoemde werkwijze.
WO2002024149A3 (fr) Antigène
AU7198291A (en) Human monoclonal antibodies against rabies viruses, the production and the use thereof
NO904333L (no) 9alfa-hydroksy-17-metylensteroider, fremgangsmaate ved fremstilling derav og anvendelse derav ved fremstilling av corticosteroider.
WO2003004049A3 (fr) Agent therapeutique
IE781880L (en) Immunogenic herpes virus subunit
WO1997002344A3 (fr) Vaccin contre des agents infectieux, composition pour le traitement et la prevention des infections a hiv
WO1991015512A3 (fr) Polypeptides d'enveloppe du vih
AU3505397A (en) Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
NL7903789A (nl) Preparaat voor het verlagen van de fenylalanine- spiegel in bloed, alsmede werkwijze voor de toepassing van het preparaat.
NZ314504A (en) Method of bending thin sheet, typically methyl methacrylate, by heating at 80 to 200 degrees centigrade for 5 seconds to 10 minutes then bending in vacuum forming station
NL191466B (nl) Voorlegering op basis van Al-Ti, alswel werkwijze voor de bereiding hiervan.
CA2238278A1 (fr) Proteine antigenique provenant de la malassezia
SE9201281D0 (sv) New human monoclonal antibodies, and a method for preparation thereof
CA2270408A1 (fr) Anticorps monoclonal contre l'epitope ypyvpdya, son procede de production et son utilisation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96196335.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AU BB BG BR CA CN CZ EE GE IS JP KP KR LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SG SI SK TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2223825

Country of ref document: CA

Ref document number: 2223825

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 1997 504866

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1996924033

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08973551

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1996924033

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1996924033

Country of ref document: EP